Our experiments with the MMP inhibitors Marimastat and SB-3CT showed for the first time that inhibition of MMP activities can reduce the expression of active integrin β1, suggesting an association between active MMP-2/MMP-9 and integrin β1 protein expression in metastatic breast cancer cells. Here, MMP9 is linked to breast carcinoma.